AGX 51
Alternative Names: AGX-51Latest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator AngioGenex
- Class Antineoplastics; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Inhibitor of differentiation protein 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 08 Jun 2020 AngioGenex has patents pending for "Compositions and Methods for Treating, Preventing and Diagnosing Cancer and Other Proliferative Disorders" in USA
- 08 Jun 2020 The option to license agreement between AngioGenex and Memorial Sloan Kettering Cancer Center has been expired, prior to June 2020